Total Payments
$188,077
2024 Payments
$246.76
Companies
28
Transactions
469
Medicare Patients
3,823
Medicare Billing
$396,019
Payment Breakdown by Category
Other$141,565 (75.3%)
Consulting$16,919 (9.0%)
Travel$16,831 (8.9%)
Food & Beverage$12,385 (6.6%)
Education$373.21 (0.2%)
Gifts$3.76 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $137,405 | 65 | 73.1% |
| Consulting Fee | $16,919 | 13 | 9.0% |
| Travel and Lodging | $16,831 | 91 | 8.9% |
| Food and Beverage | $12,385 | 290 | 6.6% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $4,160 | 1 | 2.2% |
| Education | $373.21 | 7 | 0.2% |
| Gift | $3.76 | 2 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $53,328 | 93 | $0 (2022) |
| Celgene Corporation | $45,161 | 87 | $0 (2019) |
| Actelion Pharmaceuticals US, Inc. | $22,972 | 27 | $0 (2017) |
| Helsinn Therapeutics (U.S.), Inc. | $19,861 | 26 | $0 (2019) |
| PFIZER INC. | $15,680 | 36 | $0 (2020) |
| Janssen Scientific Affairs, LLC | $10,814 | 18 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $9,467 | 36 | $0 (2021) |
| Genentech USA, Inc. | $4,284 | 8 | $0 (2018) |
| Dr.Reddy's Laboratories,Inc. | $1,959 | 6 | $0 (2017) |
| ABBVIE INC. | $1,398 | 32 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $246.76 | 2 | SUN PHARMACEUTICAL INDUSTRIES INC. ($124.97) |
| 2023 | $123.26 | 1 | Dermavant Sciences, Inc. ($123.26) |
| 2022 | $1,759 | 4 | Amgen Inc. ($1,500) |
| 2021 | $16,784 | 27 | Amgen Inc. ($16,377) |
| 2020 | $12,500 | 64 | Amgen Inc. ($11,355) |
| 2019 | $27,370 | 93 | Celgene Corporation ($17,054) |
| 2018 | $52,178 | 130 | Celgene Corporation ($22,854) |
| 2017 | $77,115 | 148 | Actelion Pharmaceuticals US, Inc. ($22,972) |
All Payment Transactions
469 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/24/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $121.79 | General |
| Category: IMMUNOLOGY | ||||||
| 05/29/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | ILUMYA (Biological) | Food and Beverage | In-kind items and services | $124.97 | General |
| Category: Dermatology | ||||||
| 01/24/2023 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $123.26 | General |
| Category: DERMATOLOGY | ||||||
| 09/01/2022 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $99.06 | General |
| Category: Dermatology | ||||||
| 04/14/2022 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $60.99 | General |
| 02/11/2022 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: Inflammation | ||||||
| 01/27/2022 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $99.06 | General |
| Category: Dermatology | ||||||
| 10/04/2021 | SUN PHARMACEUTICAL INDUSTRIES INC. | Ilumya (Biological) | Food and Beverage | In-kind items and services | $120.48 | General |
| Category: Dermatology | ||||||
| 08/12/2021 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | Cash or cash equivalent | $72.80 | General |
| Category: Inflammation | ||||||
| 08/10/2021 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | Cash or cash equivalent | $6.16 | General |
| Category: Inflammation | ||||||
| 08/05/2021 | AbbVie Inc. | — | Food and Beverage | In-kind items and services | $27.85 | General |
| 08/04/2021 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: Inflammation | ||||||
| 08/04/2021 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $500.00 | General |
| Category: Inflammation | ||||||
| 08/01/2021 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: Inflammation | ||||||
| 07/29/2021 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Inflammation | ||||||
| 07/27/2021 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $121.83 | General |
| Category: Inflammation | ||||||
| 06/11/2021 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $16.49 | General |
| 05/20/2021 | SUN PHARMACEUTICAL INDUSTRIES INC. | Ilumya (Biological) | Food and Beverage | In-kind items and services | $102.20 | General |
| Category: Dermatology | ||||||
| 05/17/2021 | Amgen Inc. | Enbrel (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,000.00 | General |
| Category: Inflammation | ||||||
| 05/11/2021 | AbbVie Inc. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $75.88 | General |
| Category: IMMUNOLOGY | ||||||
| 04/02/2021 | Amgen Inc. | Enbrel (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: Inflammation | ||||||
| 04/02/2021 | Amgen Inc. | Enbrel (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $400.00 | General |
| Category: Inflammation | ||||||
| 03/21/2021 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,000.00 | General |
| Category: Inflammation | ||||||
| 02/26/2021 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $15.91 | General |
| Category: Inflammation | ||||||
| 02/25/2021 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | Cash or cash equivalent | $6.16 | General |
| Category: Inflammation | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 45 | 45 | $7,052 | $3,245 |
| 2022 | 9 | 347 | 533 | $55,965 | $15,423 |
| 2021 | 19 | 1,173 | 1,787 | $235,894 | $69,489 |
| 2020 | 24 | 2,258 | 5,765 | $874,689 | $307,861 |
Total Patients
3,823
Total Services
8,130
Medicare Billing
$396,019
Procedure Codes
55
All Medicare Procedures & Services
55 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 18 | 18 | $2,423 | $1,266 | 52.3% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 14 | 14 | $2,381 | $1,182 | 49.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 13 | 13 | $2,248 | $796.27 | 35.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 65 | 65 | $14,854 | $3,728 | 25.1% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 80 | 81 | $10,566 | $2,789 | 26.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 43 | 44 | $7,742 | $2,765 | 35.7% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 30 | 30 | $6,719 | $1,790 | 26.6% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 27 | 27 | $5,601 | $1,559 | 27.8% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 58 | 240 | $3,088 | $1,031 | 33.4% |
| 11301 | Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | Office | 2022 | 11 | 13 | $3,365 | $803.01 | 23.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 17 | 17 | $1,727 | $622.29 | 36.0% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 16 | 16 | $2,303 | $335.94 | 14.6% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 149 | 149 | $35,120 | $11,757 | 33.5% |
| 99202 | New patient outpatient visit, total time 15-29 minutes | Office | 2021 | 185 | 185 | $27,945 | $8,525 | 30.5% |
| 96910 | Skin application of tar and ultraviolet b or petrolatum and ultraviolet b | Office | 2021 | 40 | 110 | $27,018 | $7,617 | 28.2% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 98 | 100 | $23,648 | $7,127 | 30.1% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 87 | 89 | $18,928 | $6,262 | 33.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 117 | 120 | $23,086 | $6,145 | 26.6% |
| 17000 | Destruction of skin growth | Office | 2021 | 174 | 183 | $25,329 | $5,999 | 23.7% |
| 17003 | Destruction of 2-14 skin growths | Office | 2021 | 119 | 577 | $7,781 | $2,836 | 36.5% |
| 11301 | Shaving of 0.6 centimeters to 1.0 centimeters skin growth of the trunk, arms, or legs | Office | 2021 | 23 | 27 | $7,020 | $2,225 | 31.7% |
| 17262 | Destruction of malignant growth (1.1 to 2.0 centimeters) of trunk, arms, or legs | Office | 2021 | 12 | 16 | $6,028 | $1,949 | 32.3% |
| 17004 | Destruction of 15 or more premalignant skin growths | Office | 2021 | 17 | 17 | $5,914 | $1,836 | 31.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 38 | 38 | $10,372 | $1,833 | 17.7% |
| 11302 | Shaving of 1.1 to 2.0 centimeters skin growth of the trunk, arms, or legs | Office | 2021 | 17 | 19 | $5,680 | $1,666 | 29.3% |
About Dr. Charles Camisa, M.D
Dr. Charles Camisa, M.D is a Dermatology healthcare provider based in Ft. Myers, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1376596908.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Charles Camisa, M.D has received a total of $188,077 in payments from pharmaceutical and medical device companies, with $246.76 received in 2024. These payments were reported across 469 transactions from 28 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($137,405).
As a Medicare-enrolled provider, Camisa has provided services to 3,823 Medicare beneficiaries, totaling 8,130 services with total Medicare billing of $396,019. Data is available for 4 years (2020–2023), covering 55 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Ft. Myers, FL
- Active Since 05/17/2006
- Last Updated 12/14/2020
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1376596908
Products in Payments
- Otezla (Drug) $71,366
- Enbrel (Biological) $27,123
- VALCHLOR (Drug) $19,861
- EUCRISA (Drug) $15,665
- VALCHLOR MECHLORETHAMINE (Drug) $10,524
- COSENTYX (Biological) $9,455
- STELARA (Biological) $5,816
- Rituxan (Biological) $4,346
- SKYRIZI (Biological) $612.56
- Humira (Biological) $530.15
- Tremfya (Drug) $227.90
- Ilumya (Biological) $222.68
- TALTZ (Drug) $216.01
- ILUMYA (Biological) $212.73
- OPZELURA (Drug) $198.12
- DUPIXENT (Drug) $197.06
- SILIQ (Drug) $174.05
- TREMFYA (Drug) $152.24
- QBREXZA (Drug) $145.86
- ZILXI (Drug) $134.63
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.